Hyderabad, INDIA – AXIS Clinicals Limited (AXIS), a full-service clinical research organization (CRO), announces the opening of clinical operations in China with a Phase 1 BA/BE facility in Changsha, China in the province of Hunan.
“Our New Phase 1 BA/BE Clinical Facility is established to support best in class research for innovative as well as generic pharmaceutical product development. This expansion compliments AXIS Clinicals continued growth in various geographies and is intended to assist our clients in maximizing their opportunities,” said B. Phani Bhushan Reddy, Executive Director of AXIS Clinicals – Hyderabad.
This new hospital-based facility will assist AXIS Clinicals in meeting expanding client bases within China and globally while expanding into unmet areas of pharmaceutical research needs. This increases worldwide bed capacity as well as providing significant space for future expansion due to a continuing increase in demand for our services.
Highly experienced technical team for AXIS Clinicals was instrumental in establishing the world-class CRO services in China. The plans include a state-of-the-art Bioanalytical facility meeting local and international regulatory requirements.
This new Phase 1 BA/BE Clinical facility complements AXIS Clinicals established clinical and bioanalytical facilities in India, Mexico, and the USA. The current global AXIS Clinicals sites have successfully completed many global regulatory and client audits. “We are excited about our growth opportunities in Changsha, China and have already begun expansion plans.” Added Mr. B. Phani Bhushan Reddy.
About AXIS Clinicals
AXIS Clinicals is a Global Clinical Research Organization with operations in India, China, Mexico, and the United States. AXIS Clinicals is committed to serving the biopharmaceutical industry with Quality Deliveries. The AXIS team is well-experienced in the conduct of Phase I/IIa pharmacology clinical trials including First-In-Man, BA/BE, DDI’s, Bioanalysis, and Clinical End Point Trials (Phase II-IV).
Global AXIS has 14 years of audit success with FDA-USA, MHRA-UK, INFARMED- Portugal, AFSSAPS/ANSM-France, ANVISA- Brazil, WHO, GCC, NPRA-Malaysia, MCC-South Africa, MHSD RoK, Thai GLP, Turkey MOH, NABL, and India CDSCO; and therefore has the Quality Standards to ensure the ‘Best in Class Standards’ for Changsha, China.